Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavrilimumab PK/Safety in Healthy Japanese Adults
NCT02213315Phase 1Completed
- Sponsor
- MedImmune
- Start
- Jul 2014
- Primary completion
- Dec 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mavrilimumab in rheumatoid arthritis (RA) (3 arms), sponsored by MedImmune. Primary endpoint: Pharmacokinetic profile of mavrilimumab. Started Jul 2014; status: completed.
02
Drugs
mavrilimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02213315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02213315.